Literature DB >> 12507932

Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells.

Jian-Jun Liu1, Ake Nilsson, Stina Oredsson, Vladimir Badmaev, Wan-Zhou Zhao, Rui-Dong Duan.   

Abstract

Boswellic acids are the effective components of gum resin of Boswellia serrata, which has anti-inflammatory properties. Recent studies on brain tumors and leukemic cells indicate that boswellic acids may have antiproliferative and apoptotic effects with the mechanisms being not studied in detail. We studied their antiproliferative and apoptotic effects on colon cancer cells and the pathway leading to apoptosis. HT-29 cells were treated with beta-boswellic acid (BA), keto-beta-boswellic acid (K-BA) and acetyl-keto-beta-boswellic acid (AK-BA), respectively. Apoptosis was determined by flow cytometry, by cytoplasmic DNA-histone complex and the activity of caspase-3. The cleavage of poly-(ADP-ribose)-polymerase (PARP) and expression of Fas were examined by western blot. Specific caspase inhibitors, polyclonal Fas antibody, and antagonistic Fas antibody ZB4 were employed to elucidate apoptotic pathways. DNA synthesis and cell viability were examined. Both K-BA and AK-BA increased cytoplasmic DNA-histone complex dose-dependently and increased pre-G(1) peak in flow cytometer analysis, with the effects of AK-BA being stronger than K-BA. BA only increased the formation of DNA-histone complex at a high concentration. K-BA and AK-BA increased caspase-8, caspase-9 and caspase-3 activities accompanied by cleavage of PARP. The effects of AK-BA on formation of cytoplasmic DNA histone and on caspase-3 activation were 3.7- and 3.4-fold, respectively, more effective than those induced by camptothecin. The apoptosis induced by AK-BA was inhibited completely by caspase-3 or caspase-8 inhibitor and partially by caspase-9 inhibitor. ZB4 blocked exogenous Fas ligand-induced apoptosis, but had no effect on AK-BA-induced apoptosis. AK-BA had no significant effect on expression of Fas. Apart from apoptotic effect, these acids also inhibited [(3)H]thymidine incorporation and cell viability to different extent. In conclusion, boswellic acids, particularly AK-BA and K-BA have antiproliferative and apoptotic effects in human HT-29 cells. The apoptotic effect is mediated via a pathway dependent on caspase-8 activation but independent of Fas/FasL interaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12507932     DOI: 10.1093/carcin/23.12.2087

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  42 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

2.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

3.  Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Authors:  Xiufeng Pang; Zhengfang Yi; Xiaoli Zhang; Bokyung Sung; Weijing Qu; Xiaoyuan Lian; Bharat B Aggarwal; Mingyao Liu
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

4.  Evaluation of systemic administration of Boswellia papyrifera extracts on spatial memory retention in male rats.

Authors:  Ali Mahmoudi; Ali Hosseini-Sharifabad; Hamid R Monsef-Esfahani; Ali R Yazdinejad; Mahnaz Khanavi; Ali Roghani; Cordian Beyer; Mohammad Sharifzadeh
Journal:  J Nat Med       Date:  2011-04-11       Impact factor: 2.343

5.  Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.

Authors:  Yong-Qing Liu; Shi-Kang Wang; Qing-Qing Xu; Hui-Qing Yuan; Yan-Xia Guo; Qian Wang; Feng Kong; Zhao-Min Lin; De-Qing Sun; Rong-Mei Wang; Hong-Xiang Lou
Journal:  Acta Pharmacol Sin       Date:  2018-08-31       Impact factor: 6.150

6.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for colorectal cancer.

Authors:  Kai Yang; Fan Zhang; Peng Han; Zhuo-Zhong Wang; Kui Deng; Yuan-Yuan Zhang; Wei-Wei Zhao; Wei Song; Yu-Qing Cai; Kang Li; Bin-Bin Cui; Zheng-Jiang Zhu
Journal:  Metabolomics       Date:  2018-08-16       Impact factor: 4.290

7.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

8.  Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.

Authors:  Ajaikumar B Kunnumakkara; Asha S Nair; Bokyung Sung; Manoj K Pandey; Bharat B Aggarwal
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 9.  Medicinal plants and cancer chemoprevention.

Authors:  Avni G Desai; Ghulam N Qazi; Ramesh K Ganju; Mahmoud El-Tamer; Jaswant Singh; Ajit K Saxena; Yashbir S Bedi; Subhash C Taneja; Hari K Bhat
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

10.  Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity.

Authors:  Mark Barton Frank; Qing Yang; Jeanette Osban; Joseph T Azzarello; Marcia R Saban; Ricardo Saban; Richard A Ashley; Jan C Welter; Kar-Ming Fung; Hsueh-Kung Lin
Journal:  BMC Complement Altern Med       Date:  2009-03-18       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.